Concepts (72)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 2 | 2022 | 815 | 0.930 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 924 | 0.900 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 368 | 0.520 |
Why?
|
| Multiple Myeloma | 3 | 2024 | 342 | 0.500 |
Why?
|
| Neoplasm, Residual | 3 | 2024 | 188 | 0.310 |
Why?
|
| Oligopeptides | 2 | 2024 | 190 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 2556 | 0.250 |
Why?
|
| Dexamethasone | 2 | 2024 | 347 | 0.240 |
Why?
|
| Myeloma Proteins | 1 | 2024 | 37 | 0.230 |
Why?
|
| Reimbursement, Incentive | 1 | 2022 | 38 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 170 | 0.170 |
Why?
|
| Remission Induction | 1 | 2022 | 763 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 164 | 0.170 |
Why?
|
| Hydrazines | 1 | 2020 | 32 | 0.170 |
Why?
|
| Triazoles | 1 | 2020 | 108 | 0.160 |
Why?
|
| Receptors, Fc | 1 | 2019 | 33 | 0.160 |
Why?
|
| Polysaccharides | 1 | 2019 | 93 | 0.150 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 205 | 0.140 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 380 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1399 | 0.140 |
Why?
|
| Placenta | 1 | 2019 | 187 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 460 | 0.140 |
Why?
|
| Maintenance Chemotherapy | 2 | 2024 | 86 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 95 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2013 | 134 | 0.100 |
Why?
|
| Virus Replication | 1 | 2013 | 323 | 0.100 |
Why?
|
| Humans | 9 | 2024 | 92303 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 461 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 628 | 0.080 |
Why?
|
| Liver | 1 | 2013 | 1228 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 3054 | 0.070 |
Why?
|
| Female | 6 | 2024 | 47894 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2024 | 198 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2024 | 115 | 0.050 |
Why?
|
| Adult | 4 | 2024 | 27535 | 0.050 |
Why?
|
| Middle Aged | 4 | 2024 | 27043 | 0.050 |
Why?
|
| Aged | 3 | 2024 | 19952 | 0.050 |
Why?
|
| Male | 5 | 2024 | 43924 | 0.050 |
Why?
|
| Vinblastine | 1 | 2021 | 100 | 0.050 |
Why?
|
| Bleomycin | 1 | 2021 | 103 | 0.050 |
Why?
|
| Dacarbazine | 1 | 2021 | 101 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 296 | 0.040 |
Why?
|
| Piperazines | 1 | 2022 | 288 | 0.040 |
Why?
|
| Pyridines | 1 | 2022 | 311 | 0.040 |
Why?
|
| Belgium | 1 | 2019 | 4 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 6 | 0.040 |
Why?
|
| Cell Degranulation | 1 | 2019 | 15 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2019 | 56 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 133 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 1180 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 277 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 286 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 786 | 0.030 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2013 | 16 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 6916 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2506 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 142 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 2976 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 183 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 3112 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 708 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2013 | 474 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 8727 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1902 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 9679 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1242 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 2502 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 6628 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 9491 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7346 | 0.020 |
Why?
|